Resminostat

Resminostat

Names
IUPAC name (2E)-3-[1-({4-[(Dimethylamino)methyl]phenyl}sulfonyl)-1H-pyrrol-3-yl]-N-hydroxyacrylamide
Other names RAS2410; Resminostat 4SC-201
Identifiers
CAS Registry Number	864814-88-0
ChemSpider	9784710
InChI InChI=1S/C16H19N3O4S/c1-18(2)11-13-3-6-15(7-4-13)24(22,23)19-10-9-14(12-19)5-8-16(20)17-21/h3-10,12,21H,11H2,1-2H3,(H,17,20)/b8-5+ Key: FECGNJPYVFEKOD-VMPITWQZSA-N InChI=1/C16H19N3O4S/c1-18(2)11-13-3-6-15(7-4-13)24(22,23)19-10-9-14(12-19)5-8-16(20)17-21/h3-10,12,21H,11H2,1-2H3,(H,17,20)/b8-5+ Key: FECGNJPYVFEKOD-VMPITWQZBF
Jmol-3D images	Image
PubChem	11609955
SMILES CN(C)CC1=CC=C(C=C1)S(=O)(=O)N2C=CC(=C2)/C=C/C(=O)NO
Properties
Molecular formula	C16H19N3O4S
Molar mass	349.40 g·mol−1
Density	1.282 g/cm3
Except where noted otherwise, data is given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
Infobox references

Resminostat (RAS2410) is an orally bioavailable inhibitor of histone deacetylases (HDACs), of which inhibitors are antineoplastic agents.^[1]
In 2011, the German drug maker 4SC was granted orphan drug designation for resminostat by the Food and Drug Administration for the treatment of hepatocellular cancer/HCC.^[2]

Mechanism

Resminostat restrains the phosphorylation of 4E-BP1 and p70S6k, indicating an disturbance with Akt signalling pathway.The treatment of resminostat leads to a drop of Bim and Bax protein level and Bcl-xL level.^[3]

As with other inhibitors such as pracinostat, the inhibition of HDACs by resminostat results in an accumulation of highly acetylated histones, followed by an abduction of chromatin remodeling, inhibition of tumor suppressor genes transcription and cell division, and finally tumor cell apoptosis.

References